Graf Akcie REGN (Regeneron Pharmaceuticals, Inc.). Diskuze k akciím REGN. Aktuální informace REGN.

Základní informace o společnosti Regeneron Pharmaceuticals, Inc. (Akcie REGN)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 59.2B
Hodnota podniku (EV) 66.79B
Tržby 12.384B
EBITDA 6.659B
Zisk 6.205B
Růst v tržbách Q/Q 163.24 %
Růst v tržbách Y/Y 54.84 %
P/E (Cena vůči ziskům) 9.43
Forward P/E 13.90
EV/Sales 5.39
EV/EBITDA 10.03
EV/EBIT 9.15
PEG 1.06
Price/Sales 4.85
P/FCF 35.49
Price/Book 5.45
Účetní hodnota na akcii 101.92
Hotovost na akcii 33.16
FCF vůči ceně 2.82 %
Počet zaměstnanců 9,123
Tržba na zaměstnance 1357000
Profit margin 41.35 %
Operating margin 53.94 %
Gross margin 86.82 %
EBIT margin 58.94 %
EBITDA margin 53.77 %
EPS - Zisk na akcii 58.89
EPS - Kvartální růst 290.64 %
EPS - Očekávaný růst příští rok 7.66 %
Return on assets 34.23 %
Return on equity 51.44 %
ROIC 24.19 %
ROCE 41.11 %
Dluhy/Equity 0.56
Čistý dluh/EBITDA -0.49
Current ratio 3.57
Quick Ratio 3.04
Volatilita 2.73
Beta 0.69
RSI 30.01
Cílová cena analytiků 674
Známka akcie (dle analytiků) 1.88
Insider ownership 2.96 %
Institutional ownership 90.56 %
Počet akcií 105.106M
Procento shortovaných akcií 1.76 %
Short ratio 1.86 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 1991
Země United States

Finanční výsledky akcie REGN

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$8,497.1$6,557.6$5,145.6$5,872.2$4,860.4$4,103.728
Cost Of Goods Sold$1,119.9$765.1$417.5$397.1$299.7$392.709
Gross Profit$7,377.2$5,792.5$4,728.1$5,475.1$4,560.7$3,711.019
Research And Development Expenses$2,735$2,450$1,468.8$2,075.1$2,052.3$1,620.577
SG&A Expenses$1,346$1,341.9$1,127.2$1,320.4$1,177.7$838.526
Other Operating Income Or Expenses$280.4$209.2$402.3---
Operating Expenses$4,920.5$4,347.8$2,611.2$3,792.6$3,529.7$2,851.812
Operating Income$3,576.6$2,209.8$2,534.4$2,079.6$1,330.7$1,251.916
Total Non-Operating Income/Expense$233.8$219.3$19.1$-1.1$-0.9$-26.819
Pre-Tax Income$3,810.4$2,429.1$2,553.5$2,078.5$1,329.8$1,225.097
Income Taxes$297.2$313.3$109.1$880$434.3$589.041
Income After Taxes$3,513.2$2,115.8$2,444.4$1,198.5$895.5$636.056
Other Income------
Income From Continuous Operations$3,513.2$2,115.8$2,444.4$1,198.5$895.5$636.056
Income From Discontinued Operations------
Net Income$3,513.2$2,115.8$2,444.4$1,198.5$895.5$636.056
EBITDA$3,812.5$2,420.1$2,682.6$2,225.1$1,435.4$1,326.825
EBIT$3,576.6$2,209.8$2,534.4$2,079.6$1,330.7$1,251.916
Basic Shares Outstanding108109108106105103
Shares Outstanding115115115116116115
Basic EPS$32.65$19.38$22.65$11.27$8.55$6.17
EPS - Earnings Per Share$30.52$18.46$21.29$10.34$7.70$5.52
# 2020 2019 2018 2017 2016 2015
Current Ratio3.62543.66744.46883.81772.56163.5937
Long-term Debt / Capital0.19650.06050.07480.10270.07320.0903
Debt/Equity Ratio0.24450.06440.08090.11450.10810.0993
Gross Margin86.820288.332691.886393.237693.833890.4304
Operating Margin42.09233.698349.253735.414327.378430.5068
EBIT Margin42.09233.698349.253735.414327.378430.5068
EBITDA Margin44.868236.905352.133937.892129.532632.3322
Pre-Tax Profit Margin44.843537.042549.624935.395627.359929.8533
Net Profit Margin41.345932.264947.504720.409718.424415.4995
Asset Turnover0.49510.44290.43850.670.6970.7316
Inventory Turnover Ratio0.58430.54050.36270.54690.75051.646
Receiveable Turnover2.06512.35412.29392.97433.01582.7958
Days Sales In Receivables176.7504155.0482159.12122.7171121.0273130.5507
ROE - Return On Equity31.864919.07927.912719.506520.12717.4031
Return On Tangible Equity31.864919.07927.912719.506520.12717.4031
ROA - Return On Assets20.469314.290920.830913.674812.841511.3397
ROI - Return On Investment25.604617.92525.823517.502518.653115.8311
Book Value Per Share103.0874100.562280.337857.088641.970834.9247
Operating Cash Flow Per Share1.54212.08317.8433-1.49861.22754.9144
Free Cash Flow Per Share-0.04891.67156.85820.55092.70931.9674